Overview
Title
To amend title XVIII of the Social Security Act to authorize the coverage of additional lung cancer screening tests under the Medicare program.
ELI5 AI
This bill wants to make sure older people on Medicare can get more types of tests to check for lung cancer early, like using a new flashlight to find hidden spots.
Summary AI
H. R. 1406 seeks to amend the Social Security Act to allow Medicare to cover more types of lung cancer screening tests. The bill, known as the "Lung Cancer Screening and Prevention Act of 2025," would enable the Secretary of Health to approve additional FDA-cleared lung cancer tests as preventive services for appropriate individuals. This expansion aims to enhance early detection efforts by covering these tests under Medicare Part B. The changes would take effect immediately upon the bill's enactment.
Published
Keywords AI
Sources
Bill Statistics
Size
Language
Complexity
AnalysisAI
General Summary of the Bill
The legislation, known as the "Lung Cancer Screening and Prevention Act of 2025," aims to amend Title XVIII of the Social Security Act, specifically expanding Medicare coverage to include additional lung cancer screening tests. These tests would be those that have received clearance or approval from the Food and Drug Administration (FDA). The bill empowers the Secretary of Health and Human Services to determine what constitutes appropriate tests, individuals who should receive them, and how frequently these tests should be conducted, in consultation with relevant organizations.
Summary of Significant Issues
The legislation introduces several concerns, particularly regarding the level of discretion granted to the Secretary of Health and Human Services. There is a potential for inconsistency in how screenings are made available, as terms like "appropriate individuals," "frequency," and "payment limits" are not clearly defined. Furthermore, the bill calls for consultation with organizations but does not specify which ones, potentially leading to questions about bias and favoritism. Another significant issue is the lack of a clear accountability or reporting mechanism for decisions made about test coverage, as certain determinations may bypass some existing requirements.
Impact on the Public
For the public, particularly those eligible for Medicare, the bill represents a potential improvement in access to important lung cancer screenings. Such tests can be crucial for early detection and treatment, potentially improving healthcare outcomes and reducing long-term costs associated with lung cancer treatment. However, the lack of specificity in the bill might lead to uneven access to these services. The public could face confusion about eligibility and the availability of tests if transparency is not maintained.
Impact on Specific Stakeholders
Positive Impacts:
- Medicare Beneficiaries: Individuals who qualify for Medicare could benefit from expanded screening options, potentially leading to earlier detection of lung cancer and better treatment outcomes.
- Healthcare Providers: Hospitals and clinics might see an increase in demand for lung cancer screenings, which could lead to increased revenue and better integration of preventive services in patient care.
Negative Impacts:
- Potential Patients: Without clear guidelines, some individuals might not receive the screenings they could benefit from due to overly restrictive interpretations of who is "appropriate."
- Health Insurance Administrators: The ambiguity in the bill may create challenges in policy administration, requiring careful interpretation that aligns with the Secretary's determinations.
- Organizations with Expertise in Preventive Services: The unspecified nature of which organizations will be consulted may lead to some stakeholders feeling left out, raising concerns about fairness and the comprehensiveness of expert input.
Overall, while the bill holds promise for improving preventive healthcare through expanded lung cancer screening under Medicare, it also raises essential questions about implementation details, equity, and transparency that need careful consideration and perhaps additional legislative clarification.
Issues
The language granting the Secretary discretion to determine 'appropriate individuals' and 'appropriate frequency and payment limits' in Section 2 may lack specificity, potentially leading to inconsistent application and resulting in unfair access to lung cancer screenings.
The absence of clearly defined qualifications or criteria for 'appropriate organizations' to be consulted by the Secretary, as mentioned in Section 2, may introduce bias or favoritism, impacting which lung cancer screening tests receive coverage.
The provision in Section 2 allowing the Secretary to cover new lung cancer screening tests without a requirement for determination under section 1861(ddd)(3)(B) lacks a clear accountability or reporting mechanism, risking a lack of transparency in decision-making.
The use of complex legislative references and amendments in Section 2 could make it challenging for the general public without specialized knowledge to understand the implications for Medicare coverage and eligibility for lung cancer screening tests.
Sections
Sections are presented as they are annotated in the original legislative text. Any missing headers, numbers, or non-consecutive order is due to the original text.
1. Short title Read Opens in new tab
Summary AI
The first section of the Act states that it may be officially called the "Lung Cancer Screening and Prevention Act of 2025."
2. Authority to expand coverage of tests for lung cancer screening under the medicare program Read Opens in new tab
Summary AI
The section allows the Secretary of Health and Human Services to expand Medicare coverage to include new lung cancer screening tests approved by the FDA, beyond those currently covered, as preventive services. The Secretary will decide appropriate tests and their frequency in consultation with relevant organizations, and recommendations from preventive service experts may be considered during the decision-making process.